Stock Taper
SCREENER COMPARE ANY 2 STOCKS
WVE
WAVE LIFE SCIENCES LTD.
NASDAQ
$5.04
▼ DOWN 2.33% (-0.12)

KEY STATISTICS

Market Cap$993.12 M
52w High$21.73
52w Low$5.01
Dividend Yield—
Frequency—
P/E-4.75
Volume2.22M
Shares Out.197.05M

COMPANY

LEADERSHIP

Paul Bolno
CHIEF EXECUTIVE
Paul Bolno

COMPENSATION 2026

Salary$655,500
Stock Awards$0
Incentive Plan Pay$532,600
All Other Comp.$19,266
Total$4,272,299

ABOUT

SECTOR
Healthcare
WENT PUBLIC
November 11, 2015
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
317

PRICE TARGET

Target High$18.00
Target Low$12.00
Target Median$13.00
Target Consensus$14.00

UPCOMING EARNINGS

DateNov 9, 2026
DayMonday
Rev. Est.$5.03M
NOV
9
MON

PRICE

$5.04 ▼ DOWN 2.33% (−$0.12)
$5.05$5.10$5.15$5.209:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM5.04

About Wave Life Sciences Ltd.

https://wavelifesciences.com ↗

Wave Life Sciences Ltd. is a Singapore-based clinical-stage biotech developing stereopure oligonucleotides for genetic diseases, including ALS, Huntington's, Duchenne muscular dystrophy, and retinal disorders, through its PRISM platform.

INDUSTRY

Biotechnology

A PRODUCT WAVE LIFE SCIENCES LTD. IS KNOWN FOR

WVE-007
WVE-007

WVE-007 is an investigational siRNA therapy for obesity, with Wave prioritizing its development and aiming to start a Phase 2a trial by 2026.

COMPETITORS

COMPETITOR
ALNY COMPARE
ARWR COMPARE
IONS COMPARE
SLN COMPARE
SRPT COMPARE

Revenue by Products

IconPRODUCTQ2-2021
Research Term$18.5M

ETFS HOLDING THIS STOCK

ETFS HOLDING
110
LISTED HERE
20
RANKED BY POSITION SIZE
XSU.TO
0.02% · 3.6M
VXF
0.01% · 1.8M
XPH
1.30% · 1.5M
SCHA
0.02% · 716.6K
FESM
0.03% · 430.0K
DFAS
0.01% · 386.1K
SBIO
0.49% · 236.6K
LFSC
0.63% · 157.1K
NUSC
0.05% · 133.8K
XRSG.L
0.02% · 126.2K
PRFZ
0.02% · 115.7K
GNOM
0.60% · 110.6K
OZEM
0.73% · 92.9K
SP
SPIT
1.31% · 88.9K
BBC
0.53% · 53.4K
PILL
0.87% · 41.5K
BBSC
0.03% · 38.4K
TILT
0.00% · 8.4K
BIB
0.03% · 6.9K
RESM
0.04% · 455

INSTITUTIONAL OWNERSHIP

SHARES OWNED
100.00%
HOLDERS
338
TOP 12 OF 338 · RANKED BY POSITION SIZE
Gyon Technologies Capital Management, LP
94.0M sh · $74.38K
Ra Capital Management, L.P.
27.0M sh · $156.73M
Blackrock, Inc.
19.2M sh · $111.57M
Gsk Plc
18.2M sh · $106.01M
Fmr LLC
15.1M sh · $257.31M
Adage Capital Partners Gp, L.L.C.
14.6M sh · $106.64M
Maverick Capital Ltd
10.3M sh · $59.72M
Price T Rowe Associates Inc /Md/
8.7M sh · $63.11M
Darwin Global Management, Ltd.
7.3M sh · $125.17M
Blackrock Inc.
6.7M sh · $33.63M
Driehaus Capital Management LLC
6.6M sh · $111.88M
M28 Capital Management LP
5.7M sh · $96.3M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book3
Overall Score2

INSIDER TRADES

★
DIRECTOR
Wagner Heidi L
Purchase · 7.0K shares
2026-08-11
★
DIRECTOR
Wagner Heidi L
Sale · 7.0K shares
2026-08-11
★
DIRECTOR
Rawcliffe Adrian
Sale · 12.7K shares
2026-08-12
★
DIRECTOR
TAKANASHI KEN
Sale · 3.9K shares
2026-08-11

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 7
OUTPERFORM 4
OVERWEIGHT 2
13 GRADES IN THE LAST 12 MONTHS
Mizuho OUTPERFORM B. Riley Securities BUY Wedbush OUTPERFORM Citigroup BUY Wells Fargo OVERWEIGHT HC Wainwright & Co. BUY Canaccord Genuity BUY Truist Securities BUY

SECTORS PEERS

PEERPRICE
SYRE$90.36COMPARE
ELVN$57.86COMPARE
AMLX$34.74COMPARE
PGEN$6.95COMPARE
ZBIO$31.27COMPARE
NTLA$12.87COMPARE
ORIC$13.24COMPARE
UPB$6.69COMPARE